(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing - 2The Response to Self-improvement: Embracing a Development Outlook
- 3The Electric Bicycle Americans Can Confide in 2024
- 4Which Breakfast Enraptures Your Taste Buds? Vote
- 5China Just Got A Lot Closer To Its First-Ever Manned Moon Landing
- Worldwide Objections Ideal For A Golf Outing
- Don't miss the waxing moon swing by the Beehive star cluster March 27
- Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- Can humans have babies in space? It may be harder than expected
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- 5 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- Excelling at Discussion: Genuine Examples of overcoming adversity
- How to watch NASA's Artemis 2 astronauts launch to the moon on April 1
